文献速递血液净化与透析

维持性血液透析与腹膜透析患者的处方模式及药物费用

Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究基于加拿大阿尔伯塔省2019年3月31日的2248例维持性透析成人(HD 1781例,PD 467例),分析多重用药的患病率与费用。中位药物类别数为6,每日药片负担中位8.0片,12%被处方至少一种肾衰竭禁忌药物;透析患者药片负担和费用分别较匹配的普通人群高3倍和10倍以上。

要点

  • 透析患者中位使用6类处方药,每日药片负担中位8.0片。
  • 12%的透析患者被处方至少一种肾衰竭禁忌药物。
  • 透析患者药片负担和年人均费用分别较匹配普通人群高3倍和10倍以上。

核心结论

  • 透析患者处方药物使用和相关费用显著高于普通人群,需要有效的减处方方法。

研究设计与样本

  • 基于人群的队列研究,纳入加拿大阿尔伯塔省2019年3月31日≥20岁维持性HD或PD成人共2248例(HD 1781例,PD 467例),并与年龄性别匹配的普通人群比较。

主要发现

  • 中位处方药物类别数为6(IQR 4-8),中位每日药片负担为8.0片(IQR 4.6-12.6)。
  • 5%的患者每日处方药片数≥21.7片,16.5%的患者每日处方药片数≥15片。
  • 12%的患者被处方至少一种在肾衰竭中禁忌的药物。
  • 在1063例≥65岁患者中,中位潜在不适当药物(PIM)类别数为2(IQR 1-2),中位PIM药片负担为1.2片/天(IQR 0.5-2.4)。

临床怎么用

  • 透析患者应常规评估多重用药和肾衰竭禁忌药物,关注高药片负担及费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polypharmacy is a significant clinical issue for patients on dialysis but has been incompletely studied. We investigated the prevalence and costs of polypharmacy in a population-based cohort of participants treated with haemodialysis (HD) or peritoneal dialysis (PD). METHODS: We studied adults ≥20 years of age in Alberta, Canada receiving maintenance HD or PD as of 31 March 2019. We characterized participants as users of 0-29 drug categories of interest and those ≥65 years of age as users/non-users of potentially inappropriate medications (PIMs). We calculated the number of drug categories, daily pill burden, total annual cost and annual cost per participant and compared this to an age- and sex-matched cohort from the general Alberta population. RESULTS: Among 2248 participants (mean age 63 years; 39% female) on HD (n = 1781) or PD (n = 467), the median number of prescribed drug categories was 6 [interquartile range (IQR) 4-8] and the median daily pill burden was 8.0 (IQR 4.6-12.6), with 5% prescribed ≥21.7 pills/day and 16.5% prescribed ≥15 pills/day. Twelve percent were prescribed at least one drug that is contraindicated in kidney failure. The median annual per-participant cost was ${\$}$3831, totalling ≈${\$}$11.6 million annually for all participants. When restricting to the 1063 participants ≥65 years of age, the median number of PIM categories was 2 (IQR 1-2), with a median PIM pill burden of 1.2 pills/day (IQR 0.5-2.4). Compared with PD participants, HD participants had a similar daily pill burden, higher use of PIMs and higher annual per-participant cost. Pill burden and associated costs for participants on dialysis were >3-fold and 10-fold higher, respectively, compared with the matched participants from the general population. CONCLUSION: Participants on dialysis have markedly higher use of prescription medications and associated costs than the general population. Effective methods to de-prescribe in the dialysis population are needed.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ghimire A, Lloyd AM, Bello AK, et al. Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2025. PMID: 38964833. doi:10.1093/ndt/gfae154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。